BioCentury
ARTICLE | Clinical News

NanOlogy starts Phase IIa for NanoPac in prostate cancer

December 1, 2017 9:39 PM UTC

NanOlogy LLC (Fort Worth, Texas) began a Phase IIa trial to test NanoPac in prostate cancer patients scheduled for prostatectomy.

The open-label, dose-escalation study will evaluate safety as its primary endpoint in up to 30 patients. In the dose-escalation phase, 3 cohorts of patients will be treated with intratumoral injections of 6, 10, or 15 mg/mL NanoPac 4 weeks prior to prostatectomy. Depending on the outcome of a planned DSMB analysis, a dose-confirmation phase will enroll up to an additional 12 patients...

BCIQ Company Profiles

NanOlogy LLC